Introduction
Kainate receptors (KARs) are members of the ionotropic glutamate receptor family, which also include the (S)-2-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) and Nmethyl-D-aspartate receptors (Lerma, 2006; Jane et al., 2009) . KARs modulate neurotransmitter release presynaptically, and they contribute to the slow component of the EPSC and inhibit K ϩ channels (metabotropic action) (Lerma, 2006 ) postsynaptically. There are five KAR subunits, named GluK1-5 (formerly GluR5-7 and KA-1, KA-2) (Bettler et al., 1990 (Bettler et al., , 1992 Egebjerg et al., 1991; Jane et al., 2009) . The development and functional characterization of novel potent and selective compounds is essential for understanding the contribution of KAR subtypes in neuronal processes and for the identification of new drug targets. For instance, GluK1-selective KAR antagonists have been used to investigate the involvement of GluK1 in a number of neurological disorders such as epilepsy, chronic pain, migraine, anxiety, and neurodegeneration . We have reported previously that (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxythiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione (UBP310) is a potent antagonist of GluK1-containing KARs at low nanomolar concentrations with high selectivity for GluK1 versus GluK2 and GluK3 (Dolman et al., 2007; Dargan et al., 2009 ). However, a recent study raised the possibility that UBP310 also potently antagonizes recombinant homomeric GluK3 receptors (Perrais et al., 2009) , although the affinity of this ligand for GluK1 was not characterized in this study, and so the selectivity for GluK1 over GluK3 could not be estimated. The ligand binding domain (LBD) of KARs is formed by two segments (S1 and S2) that flank the pore domain (Mayer, 2005; Jane et al., 2009 ). The LBD can be recombinantly expressed and purified as a soluble protein, which has enabled the determination of X-ray crystal structures for KAR ligand binding sites (Mayer, 2005) . The crystal structure of the antagonist UBP310 bound to the GluK1 LBD has been determined (Mayer et al., 2006 ). Whereas molecular modeling of ligand-KAR interactions has been used to design more potent and subunit-selective antagonists (Dolman et al., 2007; Dargan et al., 2009; Jane et al., 2009) , the involvement of individual amino acid residues in the subunit-selective binding of antagonists to KARs has not been established experimentally. In addition, a complication in the drug design process is that the degree of opening of the LBD of GluK1, the conformation of flexible side chains of residues in the LBD, and the position of water molecules in the binding site can vary with the structure of the interacting ligand (Mayer et al., 2006; Alushin et al., 2010) , and so information regarding the involvement of nonconserved residues in ligand binding from site-directed mutagenesis studies would facilitate the design of KAR subunit-selective antagonists. Site-directed mutagenesis of key amino acid residues likely to be involved in ligand binding is often used to confirm predictions made by molecular modeling. However, it has been reported that mutations in the LBDs of KARs that disrupt interaction with glutamate or interfere with desensitization lead to endoplasmic reticulum (ER) retention of subunit proteins (Mah et al., 2005; Valluru et al., 2005; Fleck, 2006; Gill et al., 2009) . Therefore, potential changes in the biosynthesis and trafficking of binding site mutant subunits need to be investigated carefully when site-directed mutagenesis is used for the mapping of ligand binding sites in KAR subunits.
In this study, we describe the binding characteristics of a novel radiolabeled KAR antagonist [ 3 H]UBP310 using human recombinant KAR subtypes. To date, no high-resolution structures of the LBDs of GluK2 or GluK3 in complex with antagonists have been described. Herein we describe homology models of the LBDs of GluK2 and GluK3 and their use to investigate the involvement of certain nonconserved residues in the LBDs of KARs in subunit-selective interactions with antagonists. We have used site-directed mutagenesis and ligand binding assays with the newly developed radioligand [ 3 H]UBP310 to investigate hypotheses generated as a result of our modeling studies.
Materials and Methods

Synthesis of [
3 H]UBP310. The precursor for radiolabeling, (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-4,5-dibromothiophene-3-ylmethyl)-5-methylpyrimidine-2,4-dione (UBP315), was synthesized by the method published previously (Dolman et al., 2007) . Before attempting tritiation of the ligand, we established that it was possible to replace the bromo groups on the thiophene ring with hydrogen atoms by stirring an aqueous solution of the disodium salt of UBP315 and a 10% palladium on carbon catalyst under an atmosphere of hydrogen for 24 h. A 1 H NMR spectrum of the product showed complete replacement of the bromo groups by hydrogen atoms. The same conditions were used by GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK) to conduct the tritiation of UBP315. [ 3 H]UBP310 was purified by high-performance liquid chromatography using a Prodigy ODS(2) column (Phenomenex, Torrance, CA) and an eluent of 0.1% trifluoroacetic acid in water with a gradient of 10 to 90% of 0.1% trifluoroacetic acid in acetonitrile. Detection was by UV at a wavelength of 270 nm.
Analysis of Ligand Binding Sites. The X-ray crystal structure of UBP310 in complex with the LBD of rat GluK1 (Protein Data Bank identification number 2F34) was used to build homology models of the LBDs of GluK2 and GluK3 using SWISS-MODEL (Peitsch, 1995; Arnold et al., 2006; Kiefer et al., 2009 ). The structure of UBP310 was built with Maestro, a module of the Schrödinger molecular modeling suite (Schrödinger LLC, New York, NY), and energy was minimized using the MMF94s force field in Macromodel. Docking of UBP310 into the homology models of the LBDs of GluK2 and GluK3 was carried out using the Induced Fit workflow (Schrö-dinger Suite 2009 Induced Fit Docking protocol; Glide version 5.5, Prime version 2.1; both from Schrödinger LLC) within Maestro, which carries out an initial docking using Glide, followed by optimization with Prime and then a more precise Glide docking in XP mode. The grid for Glide docking into GluK2 was calculated using the following residues: Tyr457, Ala487, Arg492, Val654, Gly657, Ala658, Asn690, Thr709, and Thr710 (residue numbers exclude the signal peptide). The corresponding residues in the LBD of GluK3 were used to set up the grid for Glide when docking UBP310 into this subunit. The following constraints were used for GluK2: NHs of Arg492 and Ala487 and CϭO of Pro485 (residues corresponding to these were selected for hydrogen bonding constraints when docking into the LBD of GluK3). The best poses from ligand docking studies and the X-ray crystal structure of the complex of the GluK1 LBD with UBP310 were examined to select potential nonconserved residues that may determine selectivity of UBP310 for GluK1. Ligand poses shown in Fig. 6 were prepared using Accelrys DS Visualizer 2.0 (Accelrys, Inc., San Diego, CA).
Mutagenesis. Mutagenesis was carried out on human GluK1-2a(Q), GluK2a(Q), and GluK3a encoding cDNAs using the QuikChange XL Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA) according to the manufacturer's protocol. All residue numbering excludes the signal peptide. All mutants were verified by full-length sequencing (Geneservice, Oxford, UK).
Cell Culture and Transfection. Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium (Sigma, Gillingham, UK) supplemented with 10% (v/v) fetal calf serum (Invitrogen Ltd., Paisley, UK), 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin (all from Invitrogen) at 37°C in a humidified atmosphere of 5% CO 2 . Cells were transiently transfected using linear polyethylenimine (PEI; molecular weight ϳ25,000; Polysciences, Warrington, PA) (Durocher et al., 2002) . In brief, DNA and PEI were mixed in 150 mM NaCl at an N/P ratio of 5:8, incubated for 20 min, and added dropwise to cells. For endoglycosidase assays, 5 g of DNA were mixed with 10 l of PEI (1 mg/ml) in 500 l of NaCl (150 mM), added to cells in a 25-cm 2 flask, and incubated for 24 h. For membrane binding assays, 10 g of DNA was mixed with 40 l of PEI (1 mg/ml) in 500 l of NaCl (150 mM), added to cells in a 175-cm 2 flask, and incubated for 48 h. HEK 293 cells stably transfected with either GluK1, GluK2, or GluK3 were grown in the presence of 0.2 mg/ml hygromycin B (Invitrogen) as described previously Nutt et al., 1994; Korczak et al., 1995) .
Preparation of Membrane Fractions from HEK 293 Cells and Rat Brains. Membrane fractions were prepared from both stably and transiently transfected cells harvested in hypotonic solution (10 mM NaHCO 3 and complete protease inhibitor cocktail; Roche Diagnostics GmbH, Mannheim, Germany) and disrupted using sonication (2 ϫ 10-s bursts at 10 W, with 20-s incubation on ice in between). Cell homogenates were then spun at 1000g for 20 min at 4°C to remove cellular debris. Membranes were pelleted at 40,000g for 20 min at 4°C and washed three times by resuspension in binding buffer (50 mM Tris, buffered with citric acid, pH 7.4) and centrifugation (40,000g, 20 min, 4°C) . After the measurement of protein concentrations using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK), membrane fractions were separated into aliquots, snap-frozen in liquid nitrogen, and stored at Ϫ80°C.
Unless indicated otherwise, native brain membrane fractions were prepared from postnatal day 1 (P1) Wistar rat pups (B&K Universal Ltd., Hull, UK). Whole brains were homogenized in 10ϫ volume of 0.32 M sucrose, 2 mM EDTA, and 10 mM HEPES, pH 7.4 (all from Sigma), with protease inhibitor cocktail (Roche Diagnostics), using a motor-driven glass-Teflon homogenizer. Tissue homogenate was spun at 1000g for 10 min at 4°C to remove nuclear fraction, and resulting supernatant was spun at 40,000g for 20 min at 4°C to yield crude membrane pellet. The pellet was resuspended in homogenization buffer, centrifuged at 40,000g for 20 min at 4°C again, and washed three times using binding buffer, with one freeze-thaw cycle between washes to disrupt glutamate-containing vesicles. The resulting pellet was resuspended in binding buffer and stored at Ϫ80°C.
Radioligand Binding Assays. For the filtration assay, cell membranes were diluted in binding buffer (50 mM Tris, buffered with citric acid, pH 7.4) and 100 to 200 g of protein was incubated with radioligand on ice, filtered using a Brandel cell harvester (model M-30; Brandel, Gaithersburg, MD), and washed three times using 2 to 4 ml of binding buffer. Radioligands used were [
3 H]UBP310, described below, and [
3 H]kainate (37 MBq/ml; PerkinElmer Life and Analytical Sciences, Waltham, MA). Radioligand binding was measured using a scintillation counter (LS6500; Beckman, High Wycombe, UK). For the centrifugation assay, saturation binding to GluK3 was determined using a polyethylene glycol 6000 precipitation-based centrifugation binding assay as described previously (Molná r et al., 1993) 
and ACET were obtained from Tocris Bioscience (Avonmouth, UK). (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxythiophene-3-ylmethyl)pyrimidine-2,4-dione) (UBP304), UBP310, kainate, and NBQX disodium salt were obtained from Ascent Scientific (Avonmouth, UK). [ 3 H]Kainate was purchased from PerkinElmer Life and Analytical Sciences.
Endoglycosidase Digestion. HEK 293 cells expressing the appropriate KAR subunits were maintained for 24 h before solubilization in lysis buffer (1% Triton X-100 and 0.1% SDS in phosphatebuffered saline, pH 7.4). Cell lysates were cleared of cellular debris by centrifugation at 28,000g for 15 min at 4°C. Equal aliquots of samples were incubated with either endoglycosidase H (EndoH; 5 mU/100 l of lysate) or endoglycasidase F (EndoF; 1 U/100 l of lysate) (Roche Diagnostics) overnight at 37°C as described previously (Molná r et al., 1995; Ball et al., 2010) and analyzed by immunoblotting.
Immunoblot Analysis. Protein samples were separated using 7% (w/v) SDS-polyacrylamide gel electrophoresis gels and transferred electrophoretically onto polyvinylidene difluoride membranes as described previously (Gallyas et al., 2003) . Rabbit polyclonal antibodies to GluK1 (20 g/ml) and GluK2/3 (1:2000 dilution; Millipore, Watford, UK) with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5000 dilution; Sigma) were used to identify KAR subunit proteins as described previously (Gallyas et al., 2003; Ball et al., 2010) . A series of antigen concentrations, primary and secondary antibody dilutions, and enhanced chemiluminescence (Roche Diagnostics) exposure times were used to optimize our experimental conditions for the linear sensitivity range of the autoradiography film (HyperfilmTM MP; GE Healthcare). Immunoreactive bands were subjected to densitometry using ImageJ (http://rsbweb.nih.gov/ ij/) to determine pixel volume (pixel intensity ϫ area). For figures, we used more exposed images in which all immunopositive bands are clearly visible.
Statistics. Statistical analysis was performed using an unpaired Student's t test. For nonequal n values, a two-sample equal variance t test was performed. For comparison of multiple sets of data, an analysis of variance (SPSS; SPSS Inc., Chicago, IL) was used. A p value less than 0.05 was considered significant ‫,)ء(‬ and a p value less than 0.01 was considered highly significant ‫.)ءء(‬ Results are presented as mean Ϯ S.E.M., and n indicates the number of independent experiments.
Results
Synthesis of [
3 H]UBP310. Previous functional studies using Ca 2ϩ fluorescence assays have shown that UBP310 and its derivative ACET are high-affinity antagonists of GluK1 homomeric receptors whereas having no effect on GluK2 homomeric receptors or GluK2/GluK5 heteromers at concentrations of up to 1 mM (Dolman et al., 2007; Dargan et al., 2009 ). In addition, an electrophysiological assay on human homomeric GluK3 receptors showed that ACET had no effect at a concentration of 1 M (Dargan et al., 2009) . Although a recent study raised the possibility that UBP310 effectively blocks recombinant homomeric GluK3 receptors (Perrais et al., 2009) , the affinity of this ligand for GluK3 and the molecular mechanisms of subunit-selective interactions of UBP310 with KARs have not been investigated in detail. Tritiation of UBP315 proceeded successfully and [ 3 H]UBP310 was obtained with a specific activity of 39.0 Ci/mmol and a radiochemical purity of 99.3% by high-performance liquid chromatography. The mass spectrum of the purified product was consistent with the proposed structure (Fig. 1) . The availability of [ 3 H]UBP310 allowed us to characterize the binding properties of UBP310 directly, without interference from confounding factors associated with the use of radiolabeled agonists such as desensitization. Differential Binding of [ 3 H]UBP310 to GluK1, GluK3, and GluK2 Kainate Receptor Subunits. Binding of [ 3 H]UBP310 to the low-affinity KAR subunits GluK1, GluK2. and GluK3 was analyzed using cell membranes from stably transfected HEK 293 cell lines ( Fig. 2A) Nutt et al., 1994; Korczak et al., 1995 An analog of UBP310 was synthesized in which two bromo groups have been added to the thiophene ring (UBP315). a, catalytic hydrogenation of the dibromo analog UBP315 lead to replacement of the bromo groups by hydrogen atoms to give UBP310 with a 100% conversion, as adjudged by 1 H NMR. Reagents for a: 2 equivalents of NaOH (aq), H 2 , 10% Pd/C. b, under the same conditions, UBP315 can also be converted to a radiolabeled form of UBP310 simply by switching tritium for hydrogen in the reaction. Reagents for b: 2 equivalents of NaOH (aq), T 2 , 10% Pd/C. addition to GluK1, UBP310 also interacts with GluK3 but not with GluK2. (Fig. 3) . The 4-fold discrepancy between the calculated K D value and the one obtained from the saturation binding assay may be explained by experimental error or it may indicate that the mechanism of binding is more complex than a simple bimolecular interaction.
The low affinity of [ 3 H]UBP310 binding to GluK3 ruled out an investigation of its binding kinetics and made the determination of K D difficult using filtration assays; therefore, we used a polyethylene glycol 6000 precipitation-based centrifugation assay (Molná r et al., 1993 (Fig. 4) produced the same rank order of affinity (see Fig. 4 legend for K i values) as reported previously using a functional Ca 2ϩ fluorescence assay: UBP310ϷACETϾUBP304ϾkainateϾUBP302ϾUBP296Ͼ NBQX (Dolman et al., 2007; Dargan et al., 2009; Jane et al., 2009 ).
Binding of [ 3 H]UBP310 to Native KARs. Previous studies identified that the expression levels of GluK1 (Bettler et al., 1990 ) and other KAR subunits (Lilliu et al., 2002) are relatively high in P1 rat brains compared with other postnatal developmental time points. Therefore, we prepared (Fig. 5A) . Furthermore, although UBP310-and GluK1-preferring agonists [such as (S)-5-iodowillardiine or (R,S)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid] (Jane et al., 1997) . In addition to P1 rat brain membranes (Fig. 5A) (Fig. 5A) . These results indicate that GluK1 and GluK3 levels with active binding sites are of low abundance, and therefore other KAR subunits are responsible for the relatively high kainate binding activity in native brain samples.
Docking of UBP310 into the LBDs of GluK2 and GluK3. To date, no X-ray crystal structures of the LBDs of GluK2 or GluK3 in complex with antagonists have been reported. We therefore produced homology models of the open form of the LBDs of GluK2 and GluK3 based on the X-ray crystal structure of the GluK1 LBD-UBP310 complex (Mayer et al., 2006) . Docking of UBP310 into the homology models of the LBDs of GluK2 and GluK3 using the Induced Fit workflow in Maestro placed UBP310 in a position similar to that observed in the X-ray crystal structure of the GluK1 LBD-UBP310 complex (Fig. 6A) . However, there are differences in key nonconserved residues that bind to UBP310 in GluK2 and GluK3 compared with GluK1 that may explain the observed lower affinity of UBP310 for these two subunits. A major difference is the switch from Thr503 in GluK1 to Ala487 in GluK2, which results in a loss of binding interactions for the ␣-amino and ␣-carboxyl groups of UBP310.
In the X-ray crystal structure of the GluK1 LBD-UBP310 complex, Met722 was modeled in two conformations with occupancies of 0.65 and 0.35, and only the latter conformation (colored cyan in Fig. 6A ) allows a favorable van der Waals contact of Met722 with the thiophene ring of UBP310 Nonspecific binding was determined using 1 mM kainate. Curves were drawn using GraphPad's one-site competition binding function (GraphPad Software Inc., San Diego, CA), and K i values were determined using the previously determined K D value of 24 nM for [ 3 H]UBP310 (Fig. 3) . (Mayer et al., 2006) . However, inspection of the homology models suggests that this favorable interaction is not possible in GluK2 and GluK3, because the bulky residues Asn690 in GluK2 and Asn691 in GluK3 force the methionine residue to adopt the alternative conformation (Fig. 6A) , which cannot form an interaction with the thiophene ring of UBP310. In addition, these asparagine residues in the GluK2 and GluK3 homology models are much closer to the thiophene ring of UBP310 than the corresponding residue Ser706 in GluK1 and are likely to hinder the adoption of the optimal conformation of UBP310 for interaction of the carboxylate group attached to the thiophene ring with Thr659 (GluK2) Fig. 6 . Conversion of subunit-selective characteristics of KAR ligand binding sites by mutations of key amino acid residues. A, comparison of the binding pockets of GluK1-3, with the four nonconserved residues highlighted (Thr503, Ser674, Ser706, and Ser726 in GluK1). Note the two alternative conformations for Met722 (the conformation that forms van der Waals interactions with the thiophene ring of UBP310 is colored cyan) that were modeled in the X-ray crystal structure of the GluK1 LBD-UBP310 complex. Middle and right, UBP310 docked into homology models of GluK2 and GluK3, respectively. B, differing residues in sites S1-T/A and S2-S/N were changed using site-directed mutagenesis to analyze their significance in subunit selectivity of UBP310. Mutants created were GluK1-T503A, GluK1-N705S/S706N, GluK2-A487T, GluK2-S689N/N690S, and GluK3-N691S.
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Thr661 (GluK3). Although we have identified two reasons why these asparagine residues may play a detrimental role in antagonist binding to GluK2 and GluK3, their influence on binding affinity will depend on the degree of opening of the LBDs, and therefore, confirmation of their role in determining UBP310 binding affinity requires point mutation studies. The switch from Ser674 in GluK1 to Ala658 in GluK2 and Ala660 in GluK3 is likely to play a minor role in explaining the lower affinity of UBP310 for GluK2 and GluK3. Inspection of the X-ray crystal structure suggests that the OH group of Ser674 in GluK1 only forms an indirect hydrogen bond via a water molecule with the 2-oxo group on the uracil ring of UBP310 and is therefore not significantly contributing to the binding affinity (Mayer et al., 2006) . The switch from Ser726 in GluK1 to Thr710 in GluK2 and Thr711 in GluK3 (Fig. 6A) would not be expected to affect the binding of UBP310, because this residue is a considerable distance away from the ligand.
Mutations of Key Amino Acids Involved in UBP310 Binding at the Ligand Binding Sites of KAR Subunits.
A comparison of the binding modes of UBP310 to GluK1, GluK2, and GluK3 suggested that Thr503 in the S1 domain of GluK1 is critical for UBP310 binding, because it forms hydrogen bonds with the ␣-amino and ␣-carboxyl groups of UBP310 (Fig. 6A) . The corresponding site in GluK2 is occupied by Ala487, whereas the GluK3 subunit like GluK1, contains a threonine (Thr489). This site was mutated in both GluK1 and GluK2 to produce GluK1-T503A and GluK2-A487T, respectively, thereby converting their subunit specificity at this site (Fig. 6) .
The second residue we identified that may play a role in ligand binding was Ser706 in the S2 domain of GluK1 (Fig.  6A ). This site is occupied by an asparagine in both GluK2 (Asn690) and GluK3 (N691), and inspection of the binding modes of UBP310 in the homology models of GluK2 and GluK3 suggested that these asparagine residues may reduce binding affinity through steric hindrance (Fig. 6A) . The res- idue immediately preceding this site is an asparagine (Asn705) in GluK1 and GluK3 (Asn690) and a serine (Ser689) in GluK2. Although this residue is not believed to participate directly in binding, it was also targeted to fully convert the subunit selectivity at this site (Fig. 6) . Thus, the double mutants GluK1-N705S/S706N and GluK2-S689N/N690S and the single mutant GluK3-N691S were created.
Comparison of the Expression Levels and Intracellular Trafficking of Wild-Type and Ligand Binding Site Mutant KAR Subunits. Recent studies reported that mutations in the ligand binding sites of KARs that disrupt interaction with glutamate or prevent conformational changes can block the export of subunit proteins from the ER to the cell surface (Fleck, 2006; Gill et al., 2009) . Although based on our molecular modeling studies of the KAR ligand binding sites, it is unlikely that any of the introduced mutations (Fig. 6 ) disrupt glutamate binding and/or conformational changes in the receptor subunits; however, it was important to investigate potential changes in KAR biogenesis. Therefore, we compared the expression levels ( Fig. 7) and trafficking ( Fig. 8 ) of wild-type (WT) and mutant GluK1, GluK2, and GluK3 subunits. To identify potential differences in GluK2 or GluK3 trafficking, we analyzed their glycosylation status by EndoH. EndoH is a highly specific endoglycosidase that cleaves asparagine-linked mannose rich oligosaccharides, typically associated with unprocessed glycoproteins in the ER. EndoH is unable to cleave highly processed complex oligosaccharides from more mature glycoproteins after they are processed in the Golgi apparatus. Therefore, EndoH sensitivity is routinely used to monitor the maturation state of glycoproteins during their biosynthesis and trafficking through the secretory pathway. Our previous study established that EndoH resistance directly correlates to the cell surface expression of KAR subunit proteins (Ball et al., 2010) . After EndoH treatment, both GluK2 and GluK3 yielded double bands in immunoblots (Fig. 8A) . The lower EndoHsensitive band displayed a molecular mass of ϳ95 kDa. EndoH insensitive upper band displayed only a minor molecular mass shift in response to EndoH digestion, which is probably due to the presence of a residual high mannose glycan in the mature subunit. Quantitative comparison of the EndoH-insensitive bands revealed no detectable differences in the proportions of WT and corresponding mutant GluK2 or GluK3 proteins that were EndoH-insensitive (Fig. 8B) . Full deglycosylation of either GluK2 or GluK3 with EndoF resulted in a single band with molecular masses (ϳ95 kDa) similar to the EndoH-sensitive component (Fig. 8A) . The GluK1-2a splice variant used here does not traffic well on its own when expressed in heterologous systems and was therefore not analyzed in detail. These results indicate that the expression levels, trafficking, and degradation rates of mutant subunit proteins are not significantly different from WT, and they are able to fold and assemble to KARs, which is required for their ER export.
Mutation 3 H]UBP310, the GluK2-A487T mutant shows significantly increased binding activity (Fig. 9A) . The GluK3-N691S mutant shows considerably increased binding to the S2-S/N site seems to confer some of the subunit specific difference in kainate affinity. Inspection of the X-ray crystal structure of kainate bound to the LBD of GluK2 (Mayer, 2005) shows that Asn690 can form hydrogen bond interactions via water molecules with the distal carboxylate of kainate. In addition, Asn690 in the S2 domain forms a direct interdomain hydrogen bond contact with Glu409 in the S1 domain that would help to stabilize the closed agonist-bound conformation. The S1-T/A site does not seem to be as important for kainate binding. This site is less important for agonists because there is a direct ionic interaction between the ␣-amino group of kainate and the terminal carboxylate of a glutamate residue (Glu707 in GluK2), and therefore, the switch from threonine to alanine in GluK2 is not as detrimental. In the antagonist-bound conformation, the distance between the S1 and S2 domains is too great to permit direct interaction of the ␣-amino group of UBP310 with Glu707. Thus, the switch from threonine to alanine in GluK2, which results in a loss of hydrogen bonds to the ␣-amino and ␣-carboxyl groups, is much more important in reducing the binding affinity of antagonists such as UBP310.
Agonist binding causes KARs to adopt alternative conformation states that drive ER export (Fleck, 2006) . Mutations in the functionally significant ligand-receptor interaction sites produced ER retention of receptors without disrupting assembly. These observations indicate that glutamate binding site mutants are fully assembled in the ER, and the trafficking is interrupted at a stage following the assembly process. Recent studies established that ionotropic glutamate receptors exist naturally in their glutamate-bound state and normally traffic from the ER to Golgi en route to the plasma membrane in a glutamate-bound conformation (Fleck, 2006) . In this study, we established that biosynthesis, trafficking, and degradation of GluK1-3 are unaffected by mutations at the S1-A/T and S2-S/N sites, and mutant subunits are able to fold and assemble to functional KARs, which is required for their ER export.
In this study, we have developed a novel radioligand [ 3 H]UBP310 and shown that it binds with high affinity to GluK1, although displaying 30-fold lower affinity for GluK3 and negligible binding to GluK2. Thus, [ 3 H]UBP310 is a useful ligand for studying the pharmacology of GluK1 and GluK3 KAR subunits. Furthermore, we have produced models of the interaction of UBP310 with the LBDs of GluK2 and GluK3 and have used point mutation studies to validate conclusions made by inspection of these models regarding the roles of the S1-A/T and S2-S/N sites in the LBDs of KARs in determining ligand selectivity. Targeting of these key residues should facilitate the design and development of new ligands with greater subunit selectivity for individual KAR subunits.
